Download this datacard
Overview
Lobbying Costs
25,000€ - 49,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
1 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
5
Lobbying Costs over the years
-
Info
BEAM Alliance
EU Transparency Register
989919136810-31 First registered on 16 Dec 2019
Goals / Remit
Since its inception in 2016, the BEAM Alliance has succeeded in uniting European Small Medium Enterprises (SMEs) working in the field of antimicrobial resistance (AMR). SMEs are recognized as the driving force of today’s innovation in the field of unmet medical need but are facing a now well acknowledged market failure. The BEAM Alliance gives its members a unique voice to propose and support policies and incentives in Europe to fix the market failure. The ultimate goal is to create market conditions attractive enough to pull back the needed support from investors and industrial partners, key stakeholders to bring medicine candidates from R&D stages to the patient.
For most stakeholders in the field of AMR (including governments, patients, industry representatives and other policy makers), BEAM is now recognised as a unique contributor helping our understanding of the complex array of cross-disciplinary issues (science, finance, and policymaking).Main EU files targeted
The BEAM Alliance is following any legal and regulatory actions intended to improve the current antimicrobial resistance (AMR) market landscape. The BEAM Alliance has thus a special interest in so-called “PULL incentives” that can facilitate the market uptake of innovative solutions against AMR. PULL incentives include financial rewards, improved valuation and pricing methodologies or reimbursement mechanisms. The BEAM Alliance also has a special focus on funding instruments able to de-risk R&D activities (so-called “PUSH incentives”). From a wider perspective, the BEAM Alliance follows all evolutions linked to the fight against AMR (stewardship policies, access to critical medicine, etc.) and more generally policies related to SMEs and innovation.
In that regard the BEAM Alliance is interacting with the EU institutions in relation to the following files and policies:
EU Action on Antimicrobial Resistance
Pharmaceutical Strategy for Europe
EU pharmaceutical legislation (Directive 2001/83/EC and Regulation (EC) No 726/2004)
Communication on “Building a European Health Union”
Europe’s Industrial Strategy
SME Strategy
EU R&D funding (Horizon 2020, Horizon Europe)Address
Head Office
29 Avenue Tony Garnier
Lyon 69007
FRANCEEU Office
29 Avenue Tony Garnier
Lyon 69007
FRANCEWebsite
-
People
Total lobbyists declared
2
Employment time Lobbyists 75% 1 25% 1 Lobbyists (Full time equivalent)
1
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
Apart from the dedicated staff mentioned above, elected Board Members (7-8) (see https://beam-alliance.eu/ for details), all with active executive positions in their own companies, are contributing pro-bono to the BEAM Alliance actions.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Trade and business associations
-
Networking
Affiliation
The BEAM Alliance is a member of the AMR Industry Alliance (https://www.amrindustryalliance.org) and of the AMR Stakeholder Network (https://epha.org/amr-stakeholder-network/)
Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
25,000€ - 49,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount nove 25,000€ - 49,999€ Intermediaries for current year
Name nove Closed year Costs
25,000€ - 49,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
Antimicrobial Resistance One Health Network#E03853#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3853 #MEMBER #C#SMEs
Groups (European Parliament)
N/A
Communication activities
As part of its activities, the BEAM Alliance is in constant interactions with stakeholders involved in the fight against AMR at the international (WHO, UN IACG, European Commission, EMA, ESCMID, EUCAST, Global AMR R&D Hub, etc.) and national (ministries of health) levels. The BEAM Alliance is mainly delivering its vision and propositions through position papers (https://beam-alliance.eu/our-actions/) and invited speakers to conferences and forums, such as the AMR conference (https://amr-conference.com/). The BEAM Alliance is also particularly active during the World Antibiotic Awareness Week (18-24 Nov), and aims at organising roundtables involving stakeholders from different horizons (including European Commission, European Parliament and other national representatives).
Other activities
None declared
Meetings
Meetings
5 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 08 Jun 2023 Location Brussels Subject Discussions on push incentives models for antibiotics DG Health Emergency Preparedness and Response Authority Attending - Pierre Delsaux (Director-General)
-
Date 29 Jun 2022 Location Brussels Subject VTC meeting on Revision of the pharmaceutical legislation and Anti-microbial resistance. Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Karolina Herbout-Borczak (Cabinet member)
- Annukka Ojala (Cabinet member)
-
Date 18 Jan 2022 Location VIRTUAL MEETING Subject To discuss HERA DG Health Emergency Preparedness and Response Authority Attending - Pierre Delsaux (Director-General)
-
Date 01 Oct 2020 Location Brussels Subject Virtual meeting about the Antimicrobial Resistance Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Annukka Ojala (Cabinet member)
-
Date 11 Sep 2020 Location Videoconference Subject Challenges faced by EU SME in the anti-microbial resistance field and the upcoming pharmaceutical strategy. Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Eszter Batta (Cabinet member)